GlassScriptPhysician profile
Sandra L Mitkos
NPI 1790015527
$1,986.69
in general payments reported to CMS, 2019-2025
25 companies · $503 in 2025
The $503 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $232 · 2022: $180 · 2023: $349 · 2024: $723 · 2025: $503.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,575.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,574.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $429.04 | 2021-2025 | |
| Lilly USA, LLC | $234.65 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $200.79 | 2024-2025 | Caplyta |
| Novo Nordisk INC | $188.05 | 2021-2024 | Ozempic, Rybelsus, Wegovy |
| Nevro Corp. | $171.93 | 2024 | Senza |
| Teva Pharmaceuticals USA, INC. | $138.58 | 2023 | Austedo Xr, Uzedy |
| Grifols USA, LLC | $94.93 | 2022-2025 | Prolastin-C Liquid |
| Idorsia Pharmaceuticals US INC | $69.62 | 2023 | Quviviq |
| Glaxosmithkline, LLC. | $69.25 | 2021-2025 | Trelegy Ellipta, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $52.39 | 2021-2023 | |
| Dexcom, INC. | $47.45 | 2024-2025 | Dexcom G6 Transmitter |
| Aimmune Therapeutics, INC. | $38.06 | 2025 | Zenpep, Vowst |
| Astrazeneca Pharmaceuticals LP | $29.55 | 2024 | |
| Harmony Biosciences LLC | $29.12 | 2025 | |
| Alkermes, INC. | $28.33 | 2025 | Aristada, Lybalvi |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $26.38 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $19.88 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $18.53 | 2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $17.68 | 2025 | Spravato |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.79 | 2025 | Jardiance |
| Paratek Pharmaceuticals, INC. | $13.73 | 2024 | Nuzyra |
| Amgen INC. | $13.64 | 2025 | Otezla, Repatha |
| Exact Sciences Corporation | $13.58 | 2023 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $13.44 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.30 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Mitkos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.